ReviewCancers2026

Preclinical-Clinical Discrepancies in Immune Checkpoint Inhibitor Efficacy for Triple-Negative Breast Cancer: Disease Stage, Antibody Properties, Biomarker Alignment, and Model Limitations.

Yuwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.